/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human therapeutics. With a market cap of $165.5 billion, the company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and AMGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the general drug manufacturers industry. AMGN has a diverse and innovative product portfolio, including blockbuster drugs like Prolia, ENBREL, and XGEVA. Amgen's robust pipeline features potential first-in-class medicines. With operations worldwide, Amgen has established a strong market presence and international sales growth, diversifying revenue and mitigating market-specific risks.